Aktuelle Aspekte der heparininduzierten Thrombozytopenie

Abstract

Heparin-induced thrombocytopenia (HIT) is a drug-mediated, prothrombotic disorder caused by immunization against platelet factor 4 (PF4)/heparin complexes. A subset of anti-PF4 /heparin antibodies is capable of intravascular platelet activation by cross-linking Fcγ receptor IIA leading to platelet count decrease and/or thrombosis. HIT can be potentially associated with devastating complications such as life-threatening thrombosis. Therefore, if HIT is strongly suspected, all sources of heparin must be stopped and an alternative non-heparin anticoagulant should be started to prevent new thromboembolic complications. However, the diagnosis of HIT based on clinical information is often difficult. This review highlights the pathophysiology of HIT, emphasizing characteristic clinical features and the role of laboratory assays in the diagnosis of HIT. In addition, a summary of current therapeutic options for patients with HIT will be provided.

• Literatur

• 1 Bakchoul T. An update on heparin-induced thrombocytopenia: diagnosis and management. Expert Opin Drug Saf 2016; 15: 787-797
• 2 Greinacher A. CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia. N Engl J Med 2015; 373: 252-261
• 3 Warkentin TE, Greinacher A, Koster A et al. American College of Chest, Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S-380S
• 4 Cuker A, Gimotty PA, Crowther MA et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012; 120: 4160-4167
• 5 Lo GK et al. Evaluation of pretest clinical score (4 Ts) for the diagnosis of heparin induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 75965
• 6 Bakchoul T, Zollner H, Greinacher A. Current insights into the laboratory diagnosis of HIT. Int J Lab Hematol 2014; 36: 296-305
• 7 Bakchoul T, Giptner A, Najaoui A et al. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7: 1260-1265
• 8 Linkins LA, Bates SM, Lee AY et al. Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood 2015; 126: 597-603
• 9 Sachs UJ, von Hesberg J, Santoso S et al. Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT). Thromb Haemostas 2011; 106: 1197-1202
• 10 Nagler M, Bachmann LM, ten Cate H et al. Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2016; 127: 546-557
• 11 Greinacher A, Michels I, Kiefel V et al. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemostas 1991; 66: 734-736
• 12 Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. Sem Thromb Haemost 2012; 38: 31-37
• 13 Linkins LA, Warkentin TE, Pai M et al. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. J Thromb Haemost 2016; 14: 1206-1210
• 14 Goel R, Ness PM, Takemoto CM et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood 2015; 125: 1470-1476